01 1Aptuit (Oxford) Ltd
01 1MAVORIXAFOR
01 1Germany
NDC Package Code : 71924-0064
Start Marketing Date : 2024-04-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
53
PharmaCompass offers a list of Mavorixafor API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Mavorixafor manufacturer or Mavorixafor supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Mavorixafor manufacturer or Mavorixafor supplier.
PharmaCompass also assists you with knowing the Mavorixafor API Price utilized in the formulation of products. Mavorixafor API Price is not always fixed or binding as the Mavorixafor Price is obtained through a variety of data sources. The Mavorixafor Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Mavorixafor manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Mavorixafor, including repackagers and relabelers. The FDA regulates Mavorixafor manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Mavorixafor API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Mavorixafor supplier is an individual or a company that provides Mavorixafor active pharmaceutical ingredient (API) or Mavorixafor finished formulations upon request. The Mavorixafor suppliers may include Mavorixafor API manufacturers, exporters, distributors and traders.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Mavorixafor as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Mavorixafor API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Mavorixafor as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Mavorixafor and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Mavorixafor NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Mavorixafor suppliers with NDC on PharmaCompass.
